CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). More Details
No risks detected for CVAC from our risk checks.
Flawless balance sheet with exceptional growth potential.
Share Price & News
How has CureVac's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CVAC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CVAC's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how CVAC performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CVAC performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is CureVac's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHave Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
1 month ago | Simply Wall StHow Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
2 months ago | Simply Wall StAnalysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Is CureVac undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CVAC ($95.65) is trading below our estimate of fair value ($1388.18)
Significantly Below Fair Value: CVAC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CVAC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CVAC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CVAC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CVAC is overvalued based on its PB Ratio (19x) compared to the US Biotechs industry average (3.7x).
How is CureVac forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVAC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CVAC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CVAC's is expected to become profitable in the next 3 years.
Revenue vs Market: CVAC's revenue (80.6% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CVAC's revenue (80.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CVAC's Return on Equity is forecast to be very high in 3 years time (68.3%).
How has CureVac performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CVAC is currently unprofitable.
Growing Profit Margin: CVAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CVAC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: CVAC has a negative Return on Equity (-14.05%), as it is currently unprofitable.
How is CureVac's financial position?
Financial Position Analysis
Short Term Liabilities: CVAC's short term assets (€915.5M) exceed its short term liabilities (€110.5M).
Long Term Liabilities: CVAC's short term assets (€915.5M) exceed its long term liabilities (€150.0M).
Debt to Equity History and Analysis
Debt Level: CVAC is debt free.
Reducing Debt: CVAC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CVAC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CVAC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 76.7% per year.
What is CureVac current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CVAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CVAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CVAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CVAC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CVAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Franz-Werner Haas (50 yo)
Dr. Franz-Werner Haas, LLD, LLM, PhD, has been Chief Executive Officer of CureVac AG since June 2020 and has been its Chief Operating Officer since 2018 and also serves as its Member of Management Board. H...
CEO Compensation Analysis
Compensation vs Market: Franz-Werner's total compensation ($USD718.06K) is below average for companies of similar size in the US market ($USD10.98M).
Compensation vs Earnings: Franz-Werner's compensation has increased whilst the company is unprofitable.
Experienced Management: CVAC's management team is considered experienced (2.8 years average tenure).
Experienced Board: CVAC's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CVAC only recently listed within the past 12 months.
CureVac N.V.'s company bio, employee growth, exchange listings and data sources
- Name: CureVac N.V.
- Ticker: CVAC
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$20.476b
- Shares outstanding: 186.16m
- Website: https://www.curevac.com
Number of Employees
- CureVac N.V.
- Friedrich-Miescher-Strasse 15
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 tha...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/13 23:15|
|End of Day Share Price||2021/04/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.